Drug intelligence / Profile preview

CIGB-845

Development stage
Unknown
Lead developer
Center for Genetic Engineering and Biotechnology
Modality
Recombinant Proteins and Enzymes, Peptides
Administration
Intranasal, Intravenous, Subcutaneous
01

Overview

CIGB-845 is a neuroprotective and neurorestorative combination therapy consisting of growth hormone-releasing peptide 6 (GHRP-6) and epidermal growth factor (EGF). Developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba, it is designed to provide a multi-target approach to central nervous system protection. EGF promotes neurogenesis and remyelination, while GHRP-6 induces the expression of endogenous neuroprotective factors, offering anti-apoptotic and anti-excitotoxic effects. The drug is primarily being advanced for the treatment of ischemic stroke, with preclinical evidence supporting its potential in amyotrophic lateral sclerosis (ALS) and autoimmune encephalitis.

Other names
GHRP-6 + EGF
02

Targets

EGFR (Epidermal growth factor receptor)GHSR (Growth hormone secretagogue receptor)

Beyond the preview

Go deeper on CIGB-845.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIGB-845.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call